PH Buch 1 INTERNATIONAL SYMPOSIUM ON GLOBAL PERSPECTIVE ON PHARMA & BIOTECH PATENTS AN OVERVIEW OF PHARMA AND BIOTECH INDUSTRY AND KEY IPR ISSUES By PADMIN.

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

Biotechnology Park of The Siberian Science Town KOLTSOVO Novosibirsk 2013.
CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
PH Buch 1 IPR - NEED FOR COMPETITIVENESS FOR TEXTILES, PHARMA AND AGRO SECTORS By PADMIN BUCH Chief Consultant GITCO LTD, Ahmedabad August 6, Vadodara.
Exploring ways to Make INDIA –A hub for Clinical Research.
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.
Lim Sei cK. Definition Examples Importance.
India’s IPR Policy on Biotechnology
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
CURRENT PHARMACEUTICAL MARKETING STRATEGY M.ABHINANDANA M.PHARM Q.A.
SWOT Analysis of Indian Industry
Why Pharmacy? “Indian pharmaceutical Industry is one of the world’s largest and most developed”
Industrials Sector Jason Kraynak and Wade Guzdanski.
Agenda Doing Business in Europe Doing Business in the UK Working together.
PH Buch 1 International Seminar on Evolvement of IPR and its Management Key IPR Issues / Provisions Affecting Business (Focus on Pharma Segment) By PADMIN.
KPGM-TiE Report.  Availability of finance. unavailability of easy and sufficient finances.  Policy framework from Government. Bureaucracy, Corruption,
1 The Lockheed Martin India Innovation Growth Program
INDIA’S XI FIVE YEAR PLAN IN THE CONTEXT OF GLOBLIZATION: A NOTE ON SCIENCE AND TECHNOLOGY POLICY.
( An IACBE Accredited Institution ) Industry Analytics Post Graduate Programme (2010 – 12) 3rd Term Alliance Business School Bangalore.
Intellectual Property and Its Role in Economic Development
PH Buch 1 SEMINAR ON EMERGING IMPORTANCE OF INTELLECTUAL PROPERTY RIGHTS PROTECTION IN INDIA - GLOBAL PERSPECTIVE PATENTS AT GLOBAL LEVEL & IMPORTANCE.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
Unprecedented Growth Opportunity BIOTECHNOLOGY. Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?
PH Buch 1 6th International Seminar Intellectual Property Rights : Advantage business The Generic Advantage & Patent Drafting Strategies By PADMIN BUCH.
Life Science and Chemical Instruments Market Revenue, Opportunity, Segment and Key Trends : FMI Estimate
PADMIN BUCH IPR Innovation & Global Market
Team Constellation Warner Chilcott DRAFT COPY.  Pharmaceutical products in women's healthcare & dermatology  Perishable in both the physical and intellectual.
Sophie Wilkinson Bayer Pharmaceuticals Case Study.
Lupin Press Meet, October 7, 2003 Lupin Press Meet October 7, 2003.
Joint Development Commissioner
Career opportunities in medical research. Basic research.
The Role of New Markets Advisors in Healthcare Case Study in Pharma.
INFOMAP CONSULTANTS PVT.LTD Business intelligence at it’s best.
1. BIOPHARMACEUTICAL Korea Where Success Knows No Limits 2 Index 1. Industry Overview3 2. Competitive Standing and Outlook9 3. Government Policies14 4.
. Department of Micro, Small and Medium Enterprises Government of Tamil Nadu New Delhi 17 March 2015 International Investment and Collaboration in Small.
Unprecedented Growth & Future Job Opportunity BIOTECHNOLOGY Dr. Sanjiv Kumar Maheshwari Professor and Dean, IFTM University, Moradabad.
Financing Healthcare Infrastructure – Perspective of the Islamic Corporation for the Development of the Private Sector (ICD) Saeed Jaweed Ahmad October.
MarketsandMarkets Presents eClinical solutions Market worth 5.98 Billion USD by 2020
Market Research Report Global and Chinese Zinc dithiophosphateIndustry, Market Research Report.
Web - Mail – Image Sensors Market Forecast ( )
MarketsandMarkets Presents Global Smartphones market is expected to reach worth US$150.3 billion by 2014
Regulatory Writing and Publishing Leads Global Regulatory Outsourcing Market – Trends and Forecast
Interesting Facts about Pharmaceutical industry
Defibrillators Business Insights - Emerging Markets such as China, India, Brazil, and Mexico to Offer New Growth Opportunities for Market Players in Near.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved CTMS Market share to reach $2bn by 2024.
MarketsandMarkets™ Presents Impact Investing Market worth 307 Billion USD by 2020.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Gene Editing Market to grow at 14% CAGR from 2016 to 2024
Clinical Trial Management System Market forecast to reach $2.4bn by 2024
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Mammalian Cells Bioreactor Market to reach $1.5 bn by 2024
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Catheters Market size to exceed.
Bioinformatics Market worth $13.3 Billion by 2020
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Legal Process Outsourcing Market to surpass $40bn by 2024: Global Market.
Important Points The pharmaceutical industry in India ranks 3rd in the world terms of volume and 14th in terms of value.India’s cost of production is.
Clinical Laboratory Services Market to grow at 6.4% CAGR from 2016 to 2024
eClinical Solutions Market Share, Size, Analysis, Regional
eClinical Solutions Market
Near Infrared Imaging Market Research and Analysis Near Infrared Imaging Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy,
Laboratory Information System (LIS) Market (Size of $1,439 million in 2014) to Witness 7% CAGR during.
MarketsandMarkets Presents Emerging Economies to Offer Significant Growth Opportunities for the Western Blotting Market html.
MarketsandMarkets Presents Pharma & Biotech companies is projected highest CAGR from 2016 to 2021 in Western Blotting Market html.
MarketsandMarkets Presents Bioinformatics Market worth $13.50 billion in
Adroit Market Research +1 (214) Single Use License: US$ 4150 Request Sample North America.
Adroit Market Research +1 (214) Single Use License: US$ 4800 Request Sample Global.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Low Power Wide Area Network.
MarketsandMarkets Presents Agricultural Biologicals Testing Market worth 1.12 Billion USD by 2021.
MarketsandMarkets Presents Blockchain in Agriculture and Food Supply Chain Market by Application, Provider, Organization Size, and Region
Prof. Kiran Kalia, Director NIPER Ahmedabad
Presentation transcript:

PH Buch 1 INTERNATIONAL SYMPOSIUM ON GLOBAL PERSPECTIVE ON PHARMA & BIOTECH PATENTS AN OVERVIEW OF PHARMA AND BIOTECH INDUSTRY AND KEY IPR ISSUES By PADMIN BUCH B. Pharm, MBA, CMC Chief Consultant GITCO LTD, Ahmedabad April 19, 2007 Ahmedabad

PH Buch 2 GITCO PATENT ASSISTANCE CELL GITCO is a multi-disciplinary consultancy organization Promoted by ICICI Bank, IDBI, State Govt. Corporations & Nationalized Banks Offers Project, Management, Financial, Industrial & Technical Consultancy Services Patent Assistance Cell is one of them

PH Buch 3 GITCO PATENT ASSISTANCE CELL Patent Awareness Patent Counseling Patent Drafting Patent Filing Twenty Seven Patents filed so far Initiated by Government of Gujarat Patent Awareness Patent Counseling Patent Drafting Patent Filing Twenty Seven Patents filed so far Initiated by Government of Gujarat

PH Buch 4 Cash Subsidy By State Government 50% (Maximum Rs. 5 Lakhs) against the expenses incurred by any organization, Institute, Individual or Industrial unit for obtaining patent registration. This assistance will be given only once per product/process per institution/individual. A pioneering initiative

PH Buch 5 Pharma Industry : The Churn Factors The Product Patent New MRP based Excise VAT Revised Schedule-M Unequal Taxation in states Price Control Dynamics of International Market

PH Buch 6 Indian Drugs and Pharmaceutical Industry - An Overview Size :US$ 5.7billion( )( ASSOCHAM ) 78%; Bulk 22% CAGR of 9.7 over last 5 years Growth of Export : 22%, Domestic Market 8% to 10% Exports estimated at US $ 3.5 Billions Also Highly fragmented Industry ◄◄◄ Gujarat occupies a Prominent 40% plus share

PH Buch 7 Where Gujarat Pharma Stands India has three distinct Pharma Clusters (Zones) of manufacturing bases. Primarily Bulk Drugs, Some Formulations Southern India (Chennai- Hyderabad Axis) III -do-Northern IndiaII Bulk Drugs, Formulation & Merchant Exports Western India (Mumbai - Gujarat Axis) I Product FocusRegionZone/ Cluster Gujarat is primarily a formulation zone

PH Buch 8 INDIAN PHARMA : OVERVIEW Strengths: Highly developed industry High Intellectual Capital India a huge market: 1.1 billion potential local patients Pro-active approach by several companies Low cost of drug development and clinical trials Strong Bio diversity Implementation of Product Patent act : Modified Provisions

PH Buch 9 Outsourcing : Contract Research and Manufacturing R&D - Different strategies for SMEs Herbal Products Contract Manufacturing Bio-technology Generic Products Patent free segments of North American & Europe Many others - for a proactive industry Low cost - high quality manufacturing hub Opportunities

PH Buch 10 BIOTECH SCENARIO (Courtesy:Biotechnology in Gujarat;Status Paper by GSBTM &

PH Buch 11 BIOTECH SCENARIO Acknowledged as an economy leveler and a tool for socio-economic development  New Diagnostic tools  Prevention based healthcare  Personalised medical treatment  Genetic testing & medicines Great contribution in Food & Agri sector Also environment friendly, energy efficient Driven by Innovation,Research & Enterprise

PH Buch 12 GLOBAL SCENARIO The Global Biotechnology market : $63 billion ( ) Compound annual growth 18% Market dominated by the United States The industry is rapidly maturing and is closer to profitability The agriculture and food segment also contributed significantly

PH Buch 13 INDIAN SCENARIO Indian Biotechnology Industry 36.5 % Around 280 Companies and revenue of over USD 1.1 billion ( ) Western region contributes 49.60% Emerging vaccine hub: Vaccines constitute the largest segment of the Indian Biopharma Industry India a competitive outsourcing destination for high-end laboratory and diagnostic testing  200 Biotech Companies employed 25,000 scientists in R &D  Total manpower in Biopharma segment is 11,800  40 National Research Institutes involving 15,000 scientists

PH Buch 14 GUJARAT SCENARIO Evolved from convergence of successful industries Spin off / dedicated units of large diversified companies(Intas,Zydus,Bayer,Cadila Pharma,Alembic,Maps,Span,Concorde,etc.) Dominated by health-care companies Product mix include:  Biopharmaceuticals  Diagnostic kits/equipments  Animal health-care products  Preventive medicines Significant presence in agri-biotech Sector Has leading CROs : Quintiles, Lambda, Synchron,

PH Buch 15 GUJARAT SCENARIO 40 biotech companies & 66 support organisations Average annual turnover of the industry to the tune of Rs Crores Investment worth Rs.200 crores between Proactive role of the State Government(Dept.of Science & Technology and GSBTM) Interphase among Industry,Academia,Research Organisations & Government

PH Buch 16 Business Case: Biotech in Gujarat Source:

PH Buch 17 The Patents (Amendment) Act 2005 (Indian Patent Act) The Patents (Amendment) Act 2005 (Indian Patent Act) Key Provisions Relevant to Pharma & Implications

PH Buch 18 Patent Act : Key Provisions and implications : Patentability Criteria Only Really New entity can be patented Difficult to seek Patent Extension on the basis of moderate improvements Opportunity for early entry of Generics in India Market Would benefit Generic Players

PH Buch 19 Patent Act : Key Provisions & its Impact Pre-Grant Opposition Most patent applications, especially with incremental modifications are likely to be keenly contested Benefit to Indian Generic Manufacturers and consumers On Flip side : delay for even genuine applications

PH Buch 20 Impact Analysis : Immediate Impact “Drugs based on Post-1995 molecules already being manufactured and sold in domestic market can continue … ……….. On payment of a reasonable royalty to the patent holder. Such liability would accrue prospectively after granting Patent in India”

PH Buch 21 Immediate Impact Almost no existing products (launched before 2005 in India) in the market would have to be withdrawn. Lack of clarity on “Reasonable Royalty” Estimates : 2-4% of revenue from the product.

PH Buch 22 Patent Litigations Threat Many Small Companies not aware of IP issues May face Litigations in future Patent Litigations are very costly Essential to perform Patent Analysis/ Mapping for newer drugs Also while acquiring a company : IPR Valuation

PH Buch 23 In-Licensing Opportunity Right given by Patent holder For marketing and distribution of Patented Drugs In return of Royalty or Profit sharing In-licensing to accelerate in next 3-4 years Opportunity for companies with strong domestic presence Also for niche players with strength in specific therapeutic segments

PH Buch 24 Contract Manufacturing Opportunity Outsourcing (Formulations and Bulk Drugs) Market : US $ 40 billions $ 900 millions in 2010 Contract Manufacturing in Domestic Market : Rs.10,000 crores Opportunity for Pro-active Small and Medium Units Plant set-up to be of standards required by Market / Regulatory Agencies Higher Investment and Professional Management Approach/Attitude

PH Buch 25 To adopt to the new Patent Regime, new business models would be in focus a) Contract Research b) Contract Manufacturing c) Co-marketing Alliances Herbal products ?

PH Buch 26 India can Do It For India, possibilities are endless Large educational infrastructure  Over 200 Universities  Over 1500 Research Institutes  Over 400 PhDs a year  8000 Pharma Graduates from 500 colleges IPR laws and mechanism being strengthened Curriculum of Institutions being revised Knowledge is India’s Intellectual Property Required : business like approach from all Signs are Positive : India will do it

PH Buch 27 India and Gujarat have the potential to emerge as the Major R&D and Contract Manufacturing Hub…... … It surely will happen

PH Buch 28 THANK YOU Padmin Buch... GITCO Limited GITCO HOUSE Opp: Sardar Patel Stadium Navrangpura Ahmedabad Ph. No. (079) ; ; Fax : THANK YOU Padmin Buch... GITCO Limited GITCO HOUSE Opp: Sardar Patel Stadium Navrangpura Ahmedabad Ph. No. (079) ; ; Fax :